Q3 EPS Forecast for Capricor Therapeutics Reduced by Analyst

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – HC Wainwright reduced their Q3 2025 earnings per share estimates for Capricor Therapeutics in a research note issued on Tuesday, August 12th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings of ($0.57) per share for the quarter, down from their prior forecast of ($0.52). HC Wainwright currently has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Capricor Therapeutics’ Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.23) EPS and FY2026 earnings at ($0.88) EPS.

A number of other equities research analysts also recently commented on CAPR. Jones Trading decreased their target price on Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating for the company in a report on Wednesday, June 25th. B. Riley started coverage on Capricor Therapeutics in a report on Thursday, June 26th. They set a “buy” rating and a $21.00 target price for the company. Alliance Global Partners reaffirmed a “buy” rating on shares of Capricor Therapeutics in a report on Monday, July 14th. Piper Sandler reaffirmed an “overweight” rating and set a $20.00 target price on shares of Capricor Therapeutics in a report on Friday, July 11th. Finally, Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.56.

Capricor Therapeutics Stock Up 2.3%

Capricor Therapeutics stock opened at $7.96 on Thursday. Capricor Therapeutics has a 52 week low of $3.84 and a 52 week high of $23.40. The company has a market capitalization of $363.91 million, a price-to-earnings ratio of -4.85 and a beta of 0.59. The stock has a 50-day moving average price of $9.17 and a 200 day moving average price of $10.99.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. grew its holdings in Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. grew its holdings in Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 2,947 shares during the period. Virtus ETF Advisers LLC acquired a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $68,000. Tower Research Capital LLC TRC grew its holdings in Capricor Therapeutics by 280.8% in the second quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares during the period. Finally, Citizens Financial Group Inc. RI acquired a new stake in Capricor Therapeutics in the first quarter valued at approximately $95,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.